Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BY-NC-NDImmuno-oncology technology

Age-related tumor mutational burden and inflammaging: a pan-cancer multi-omics study of treatment-naïve patients

  • S. Yajima1
  • Y. Tsukada2
  • Y. Sota2
  • S.J.-Y. Ohtani-Kim3
  • R. Yamashita4
  • T. Fujisawa5
  • T. Kuwata6
  • G. Ishii7
  • N. Gabelia8
  • H. Juhl8
  • S. Takasu9
  • M. Takahashi10
4 more authors
  • H. Bando5
  • T. Yoshino11
  • M. Ito2
  • H. Masuda1
11 affiliations
  1. 1Department of Urology, National Cancer Center Hospital East, Kashiwa, Japan
  2. 2Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan
  3. 3Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan
  4. 4Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan
  5. 5Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
  6. 6Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan
  7. 7Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan
  8. 8Department of Indivumed GmbH, Hamburg, Germany
  9. 9Local Support Office/Clinical Research Coordinator Office, National Cancer Center Hospital East, Kashiwa, Japan
  10. 10Translational Research Sample Management Office, National Cancer Center Hospital East, Kashiwa, Japan
  11. 11Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Read full textPDFCite

Related

  1. Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial.
    Y Nakamura, T Esaki, T Nishina +15
    ESMO openPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Chronic Kidney Disease–Associated Pruritus in Danish Dialysis Patients: A Cross-Sectional Multicenter Study of Prevalence, Disease Burden, and Current Treatment Practices
    Gustav Ø. Larsen, Krista D. Kjærgaard, Christian F. Christiansen +7
    Kidney medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. "It's Like a Marathon": A Qualitative Study of Symptom Burden and Adaptation Among Patients with Oxaliplatin-Induced Peripheral Neuropathy During Treatment.
    Yi Zhang, Jing Han, Wen Gong +1
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMC
  4. Economic burden and quality of life of IgG4-related disease in China: A comparative analysis of three treatment regimens.
    Yifei Wang, Jialing Jiang, Yuxue Nie +11
    Rheumatology and immunology researchPeer-reviewedCC BYFull text1 citedGeneral medicineEurope PMC
  5. Treatment burden and health-related quality of life in adults with multiple conditions: a cross-sectional study of associated factors
    Zhaoxuan Wang, Kang Wang, Xin Zhang +7
    Frontiers in Public HealthPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{yajima2026agerelated,
  title = {{Age-related tumor mutational burden and inflammaging: a pan-cancer multi-omics study of treatment-naïve patients}},
  author = {S. Yajima and Y. Tsukada and Y. Sota and S.J.-Y. Ohtani-Kim and R. Yamashita and T. Fujisawa and T. Kuwata and G. Ishii and N. Gabelia and H. Juhl and S. Takasu and M. Takahashi and H. Bando and T. Yoshino and M. Ito and H. Masuda},
  journal = {Immuno-oncology technology},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13654048},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Age-related tumor mutational burden and inflammaging: a pan-cancer multi-omics study of treatment-naïve patients
AU  - S. Yajima
AU  - Y. Tsukada
AU  - Y. Sota
AU  - S.J.-Y. Ohtani-Kim
AU  - R. Yamashita
AU  - T. Fujisawa
AU  - T. Kuwata
AU  - G. Ishii
AU  - N. Gabelia
AU  - H. Juhl
AU  - S. Takasu
AU  - M. Takahashi
AU  - H. Bando
AU  - T. Yoshino
AU  - M. Ito
AU  - H. Masuda
PY  - 2026
DA  - 2026/09/30
JO  - Immuno-oncology technology
UR  - https://europepmc.org/article/PMC/PMC13654048
SN  - 2590-0188
ER  -